Diabetes Care, Vol 19, Issue 2 151-156, Copyright © 1996 by American Diabetes Association

ARTICLES

Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy

Y Iwamoto, K Kosaka, T Kuzuya, Y Akanuma, Y Shigeta and T Kaneko
Diabetes Center, Tokyo Women's Medical College, Japan.

OBJECTIVE: To investigate the clinical efficacy of troglitazone, a newly developed oral hypoglycemic agent, in patients with NIDDM. RESEARCH DESIGN AND METHODS: There were 284 NIDDM patients (20-82 years of age) whose glycemic control while on a diet was judged stable but was judged unsatisfactory (fasting plasma glucose [FPG] > or = 8.3 mmol/l) when entered into a multicenter and double-blind study with parallel groups study. They were randomly allocated into two groups, the troglitazone group (the T group: 400 mg/day p.o.) and the placebo group (the P group), and were treated with test drugs for 12 weeks. RESULTS: We evaluated efficacy in 136 patients of the T group and 126 patients of the P group. There was no significant difference in any of baseline characteristics between the T and P groups. In the T group, FPG and HbA1c decreased significantly after treatment (before versus after, FPG 10.1 +/- 1.6 vs. 8.8 +/- 1.9 mmol/l, P < 0.001; HbA1c: 8.6 +/- 1.5 vs 8.1 +/- 1.7%, P < 0.001). FPG and HbA1c did not change after treatment in the P group (before versus after, FPG 10.1 +/- 1.8 vs. 9.9 +/- 2.1 mmol/l; HbA1c 8.5 +/- 1.5 vs. 8.6 +/- 1.6%). Of 136 patients in the T group, 62 (45.6%) were classified as responders. Serum triglyceride level also decreased in the T group but not in the P group. Body weight increased slightly only in the T group. There were no differences in changes in blood pressure between the two groups. No serious adverse events occurred in either group. CONCLUSIONS: Troglitazone at 400 mg/day decreased FPG and HbA1c significantly in NIDDM patients who had failed to respond to diet therapy. Troglitazone, developed as a drug to enhance insulin action, can be a useful hypoglycemic agent for the treatment of NIDDM.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. L. Parchman, J. A. Pugh, C.-P. Wang, and R. L. Romero Glucose Control, Self-Care Behaviors, and the Presence of the Chronic Care Model in Primary Care Clinics Diabetes Care, November 1, 2007; 30(11): 2849 - 2854. [Abstract] [Full Text] [PDF]

				W.S. Leslie, C.R. Hankey, and M.E.J. Lean Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review QJM, July 1, 2007; 100(7): 395 - 404. [Abstract] [Full Text] [PDF]

				Y. Miyazaki, E. De Filippis, M. Bajaj, E. Wajcberg, L. Glass, C. Triplitt, E. Cersosimo, L. J Mandarino, and R. A Defronzo Predictors of improved glycaemic control with rosiglitazone therapy in type 2 diabetic patients: a practical approach for the primary care physician The British Journal of Diabetes & Vascular Disease, January 1, 2005; 5(1): 28 - 35. [Abstract] [PDF]

				Y. Miyazaki, A. Mahankali, E. Wajcberg, M. Bajaj, L. J. Mandarino, and R. A. DeFronzo Effect of Pioglitazone on Circulating Adipocytokine Levels and Insulin Sensitivity in Type 2 Diabetic Patients J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4312 - 4319. [Abstract] [Full Text] [PDF]

				H. Bays, L. Mandarino, and R. A. DeFronzo Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 463 - 478. [Full Text] [PDF]

				D.-H. Cho, Y. J. Choi, S. A. Jo, and I. Jo Nitric Oxide Production and Regulation of Endothelial Nitric-oxide Synthase Phosphorylation by Prolonged Treatment with Troglitazone: EVIDENCE FOR INVOLVEMENT OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) {gamma}-DEPENDENT AND PPAR{gamma}-INDEPENDENT SIGNALING PATHWAYS J. Biol. Chem., January 23, 2004; 279(4): 2499 - 2506. [Abstract] [Full Text] [PDF]

				M. L. Parchman, T. G. Arambula-Solomon, P. H. Noel, A. C. Larme, and J. A. Pugh Stage of Change Advancement for Diabetes Self-Management Behaviors and Glucose Control The Diabetes Educator, January 1, 2003; 29(1): 128 - 134. [Abstract] [PDF]

				J. G. Yu, S. Javorschi, A. L. Hevener, Y. T. Kruszynska, R. A. Norman, M. Sinha, and J. M. Olefsky The Effect of Thiazolidinediones on Plasma Adiponectin Levels in Normal, Obese, and Type 2 Diabetic Subjects Diabetes, October 1, 2002; 51(10): 2968 - 2974. [Abstract] [Full Text] [PDF]

				J. Rosenstock, S. G. Shen, M. R. Gatlin, and J. E. Foley Combination Therapy With Nateglinide and a Thiazolidinedione Improves Glycemic Control in Type 2 Diabetes Diabetes Care, September 1, 2002; 25(9): 1529 - 1533. [Abstract] [Full Text] [PDF]

				J. M. Miles, L. Leiter, P. Hollander, T. Wadden, J. W. Anderson, M. Doyle, J. Foreyt, L. Aronne, and S. Klein Effect of Orlistat in Overweight and Obese Patients With Type 2 Diabetes Treated With Metformin Diabetes Care, July 1, 2002; 25(7): 1123 - 1128. [Abstract] [Full Text] [PDF]

				Y. Miyazaki, A. Mahankali, M. Matsuda, S. Mahankali, J. Hardies, K. Cusi, L. J. Mandarino, and R. A. DeFronzo Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2784 - 2791. [Abstract] [Full Text] [PDF]

				N. V. Chu, A. P. S. Kong, D. D. Kim, D. Armstrong, S. Baxi, R. Deutsch, M. Caulfield, S. R. Mudaliar, R. Reitz, R. R. Henry, et al. Differential Effects of Metformin and Troglitazone on Cardiovascular Risk Factors in Patients With Type 2 Diabetes Diabetes Care, March 1, 2002; 25(3): 542 - 549. [Abstract] [Full Text] [PDF]

				M. Emoto, T. Anno, Y. Sato, K. Tanabe, S. Okuya, Y. Tanizawa, A. Matsutani, and Y. Oka Troglitazone Treatment Increases Plasma Vascular Endothelial Growth Factor in Diabetic Patients and Its mRNA in 3T3-L1 Adipocytes Diabetes, May 1, 2001; 50(5): 1166 - 1170. [Abstract] [Full Text]

				H. E. Lebovitz, J. F. Dole, R. Patwardhan, E. B. Rappaport, and M. I. Freed Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 280 - 288. [Abstract] [Full Text]

				T. Takagi, T. Akasaka, A. Yamamuro, Y. Honda, T. Hozumi, S. Morioka, and K. Yoshida Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: A serial intravascular ultrasound study J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1529 - 1535. [Abstract] [Full Text] [PDF]

				E. Y. Oh, K. M. Min, J. H. Chung, Y.-K. Min, M.-S. Lee, K.-W. Kim, and M.-K. Lee Significance of Pro12Ala Mutation in Peroxisome Proliferator-Activated Receptor-{gamma}2 in Korean Diabetic and Obese Subjects J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1801 - 1804. [Abstract] [Full Text]

				R. A. DeFronzo Pharmacologic Therapy for Type 2 Diabetes Mellitus Ann Intern Med, August 17, 1999; 131(4): 281 - 303. [Abstract] [Full Text] [PDF]

				J. E. Gerich The Genetic Basis of Type 2 Diabetes Mellitus: Impaired Insulin Secretion versus Impaired Insulin Sensitivity Endocr. Rev., August 1, 1998; 19(4): 491 - 503. [Abstract] [Full Text] [PDF]

				S. E. Inzucchi, D. G. Maggs, G. R. Spollett, S. L. Page, F. S. Rife, V. Walton, and G. I. Shulman Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus N. Engl. J. Med., March 26, 1998; 338(13): 867 - 873. [Abstract] [Full Text] [PDF]

				H. Imura A Novel Antidiabetic Drug, Troglitazone -- Reason for Hope and Concern N. Engl. J. Med., March 26, 1998; 338(13): 908 - 909. [Full Text]

				M. P. Stern The Effect of Glycemic Control on the Incidence of Macrovascular Complications of Type 2 Diabetes Arch Fam Med, March 1, 1998; 7(2): 155 - 162. [Abstract] [Full Text] [PDF]